Indianapolis, IN, United States of America

Richard N Booher

This inventor holds 30 USPTO granted patents, primarily in Heterocyclic Chemistry. Top assignees: Eli Lilly and Company, Eli Lilly Company. Active years: 1976-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard N Booher. Retrieved from https://idiyas.com/inventor/richard-n-booher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30

% Patents Active = 100.0

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 75(Granted Patents)

Company Filing History:

29 out of 4,514

Eli Lilly and Company

Years Active: 1976-1998

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Tetrahydrobenzindoles

Pyrazoloquinolines

Decahydroquinolines

Pyrimidine

Thiazolo

Alkylation

1,3-Propandiol

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5783590 - 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz�CD!indoles (1998-07-21),

2. 5750554 - 6 heterocyclic-4-amino-1,3,4,5-tetrahydrobenz�CD!indoles (1998-05-12),

3. 5736562 - 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz�CD ! indoles (1998-04-07),

4. 5674884 - 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz �cd! indoles (1997-10-07),

5. 5665758 - 6-Heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD] indoles (1997-09-09),

6. 5665744 - 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenzn [cd] indoles (1997-09-09),

7. 5665743 - 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD] indoles (1997-09-09),

8. 5656653 - 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz[cd]indoles (1997-08-12),

9. 5654324 - 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz[cd]indoles (1997-08-05),

10. 5648356 - 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[CD]indoles (1997-07-15),

11. 5643934 - 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz [CD]indoles (1997-07-01),

12. 5643930 - 6-heterocyclic-4-amino-1,3,4,5,-tetrahydrobenz [cd]indoles (1997-07-01),

13. 5643910 - 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz[CD]indoles (1997-07-01),

14. 5641797 - 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[cd] indoles (1997-06-24),

15. 5641794 - 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles (1997-06-24),

Title: Richard N Booher: Innovator in Serotonin Modulation Solutions

Introduction

Richard N Booher is an accomplished inventor based in Indianapolis, IN, with an impressive portfolio comprising 30 patents. His innovative contributions have significantly impacted the field of serotonin modulation, leading to advancements in mammalian function modification.

Latest Patents

Among his latest patents are two notable inventions: the 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz-indoles and the 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz-indoles. These compounds have been developed to enhance and modify the function of serotonin in mammals, showcasing Booher's dedication to scientific advancement.

Career Highlights

Richard Booher has held significant positions at renowned companies, including Eli Lilly and Company. His work in the pharmaceutical industry has been instrumental in developing therapeutic solutions that address various neurological conditions influenced by serotonin levels.

Collaborations

Throughout his career, Booher has collaborated with esteemed professionals, including John M Schaus and David E Lawhorn. These partnerships have fostered innovative research and development, furthering the impact of his inventions on health and medicine.

Conclusion

In conclusion, Richard N Booher stands out as a prominent inventor in the field of serotonin modulation. With a remarkable number of patents and significant contributions to pharmaceutical advancements, his work continues to influence the landscape of medical research and innovation.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]